SCHEMBL9852337

SCHEMBL9852337

CC(C)(C)c1ccc(-c2nsc(N)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.59
ADORA2A P29274 1/20 0.59
ADORA2B P29275 1/20 0.59
ADORA1 P30542 1/20 0.59
NPC1 O15118 6/20 0.58
RAB9A P51151 6/20 0.58
KDM4E B2RXH2 3/20 0.49
CYP19A1 P11511 1/20 0.44
KIF11 P52732 1/20 0.41
XDH P47989 1/20 0.41
TP53 P04637 4/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MITF O75030 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11332250 0.79 ADORA3 (0.66) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL14755751 0.79 RAB9A (0.49) NPC1RAB9AKDM4ECYP19A1KIF11
SCHEMBL15071937 0.77 ADORA3 (0.49) ADORA3ADORA2AADORA2BADORA1NPC1
SCHEMBL20390644 0.76 ADORA3 (0.66) ADORA3ADORA2AADORA2BADORA1NPC1
SCHEMBL16238754 0.76 ADORA3 (0.66) ADORA3ADORA2AADORA2BADORA1RAB9A
SCHEMBL20390138 0.76 ADORA3 (0.66) ADORA3ADORA2AADORA2BADORA1NPC1
SCHEMBL9852272 0.76 ADORA3 (0.66) ADORA3ADORA2AADORA2BADORA1NPC1
SCHEMBL9108544 0.76 ADORA3 (0.66) ADORA3ADORA2AADORA2BADORA1NPC1
SCHEMBL13659745 0.75 ADORA3 (0.59) ADORA3ADORA2AADORA2BADORA1NPC1
SCHEMBL13822161 0.75 ADORA3 (0.59) ADORA3ADORA2AADORA2BADORA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2014-07-03 US disclosed
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
EP-0455356-A1 Substituted 5-amino-1,2,4-thiadiazoles with pharmaceutical activity LILLY INDUSTRIES LIMITED (GB) 1991-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 ADORA3 2250/4885ADORA2A 2930/4885ADORA2B 2210/4885
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 ADORA3 2250/4885ADORA2A 2930/4885ADORA2B 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.